Replies to post #14781 on Hemispherx BioPharma (HEB)

[drkazmd65]

I have already obtained a copy of the Arrowhead report back when it came out. Will look for a copy of the Chardan version.

re: you business concern. They are a tiny biotech trying to do great things. Creating drugs, the facilities to produce them and getting them approved is very complicated business. Biotech sector is a risky business - high risk = high reward. Often, things do not go smoothly.

Am fully aware of this,... my issue is mostly a concern that in 30-odd years of being a 'tiny biotech trying to do great things' - management has shown a history of regularly over-promising and under-delivering, looking like they are attempting to take shortcuts (maybe they haven't but there is the appearance of it), and not quite doing what the FDA wants them to do.

I think that the biggest potential for HEB is in figuring out a treatment that works for at least some CFS patients,... and the work they have collaborated on during the last year to get a better handle on a biomarker and better diagnostic system in place for actual CFS is a solid step forward.

I got into HEB back when the pre-clinical testing successes against Ebola popped up during the Winter of 2014-2015 - although I had given the company a look or two in years prior to that point. I think that Ampligen is probably the bigger long-term winner here, just hadn't looked in detail at the information about the LDO Alferon.